Sir,
We appreciate the article written by Shrestha et al. titled, "Iodine status among subclinical and overt hypothyroid parents by urinary iodine assay" in the last issue our journal. [1] They have recommended reappraisal of salt iodization campaign to monitor for iodine excess which could be related to hypofunctioning of thyroid gland. However, there are certain clarifications requested to the authors regarding their observations that fortified iodine levels in consumed salt may be a major causative factor for thyroid dysfunction. The role of excess iodine in inhibiting release of thyroid hormone needs to be addressed carefully. Especially, if excess iodine should cause thyroid dysfunction, the actual source of excess iodine among the study population needs to be well defined and it could be in food, water, and salt, [2] and dose-response relationships inclusive of borderline excess intake and susceptibility factors for subclinical hypothyroidism and related thyroid antibody status need to be discussed.
This study would have been more informative if goiter characteristics of the study population were also included. Implementation of universal salt iodization (USI) program has been successful in improving iodine deficiency status in many developing countries, and decreasing goiter rates after an increase in urinary iodine concentrations following USI programs have been reported recently in China and Uganda. [3] Recent publication documenting increasing goiter rates at 13.5% and only 18.2% of households using iodized salt in the state of Tamil Nadu as per the survey done by Pandav et al. [4] strongly support and justify increase in iodine ppm content of consumed salt by our vulnerable populations.
There are several publications demonstrating drinking water and food with high iodine content accounting for excess of iodine while iodized salt may be the least contributor as per reports. The role of goitrogens is crucial in that there is improper utilization of iodine by thyroid gland, and to overcome this, appropriate increases in salt iodization are necessary.
As per literature search by Leung and Braverman [5] at one end of spectrum, people without any evidence of thyroid disease almost always remain euthyroid even if they consumed excess iodine and there is an escape from acute inhibitory effects of excess intrathyroidal iodide on organification process and, subsequently, thyroid hormone synthesis and adaptation to Wolff-Chaikoff effect occurs. At the other end, although underlying mechanism of iodine-induced hypothyroidism is controversial, it could be attributed to failure to adapt to Wolff-Chaikoff effect most probably due to a damaged thyroid as a result of previous pathological insults.
Sir, Anacetrapib is a potent inhibitor of cholesteryl ester transfer protein (CETP), which doubles high-density lipoprotein (HDL) cholesterol and lowers low-density lipoprotein (LDL) cholesterol. [1] Epidemiologic studies have shown inverse associations between HDL cholesterol levels and cardiovascular (CV) outcomes. Ference et al. showed that with every 1 mmol/L reduction in the LDL cholesterol levels, the risk of coronary events and ischemic stroke reduces by approximately 20%. [2] Pharmacologic inhibition of CETP has the potential to substantially increase HDL cholesterol levels, along with reductions in non-HDL portion. Due to this dual effect, it was postulated that CETP inhibitors may result in significant CV risk reduction and thus have generated considerable research interest in the past few years. Previous trials of CETP inhibitors, i.e., torcetrapib [3] and evacetrapib [4] were stopped after around 2 years due to unexpected cardiovascular hazards or apparent lack of efficacy. Recently, published REVEAL study [1] assessed the efficacy and safety of anacetrapib, a potent CETP inhibitor among patients with established occlusive vascular disease. The drug when added to effective doses of atorvastatin showed 9% reduction in CV events. Detailed examination of the study reveals the following: • Substantial HDL elevation (104% proportional difference) and LDL reduction (41% proportional difference) by anacetrapib did not get translated into proportional CV benefits • There is a direct correlation of LDL reduction to risk reduction, proven in numerous studies, but this is not exhibited in this study. Similar observations were seen with other CETP inhibitors; evacetrapib and torcetrapib which showed 31.1% and 24.9% LDL reduction, respectively, with no clinical benefits. This aspect needs more research
• The study showed benefits only in participants with higher baseline LDL (>66 mg/dL), with no benefits seen in first 2 years • The subgroup analysis revealed that patients on low dose statins benefitted more. The drug is not found as effective in females and patients with prior cerebrovascular disease, PAD and HF. This narrows the clinical utility of the drug.
It can be concluded that CETP inhibition as a therapeutic target is doubtful. Previous observational study in Japanese-American men (Honolulu Heart Program) with mutation in the CETP gene showed increased Coronary Heart Disease (adjusted RR of 1.68) despite increased HDL levels. [5] This finding suggests that not only HDL concentration but also the dynamics of cholesterol transport through HDL (i.e., reverse cholesterol transport) determine the antiatherogenicity of the HDL fraction.
The REVEAL study showed a good safety profile of anacetrapib. One possible therapeutic utility of the molecule can be in patients who are unable to tolerate statins, so the drug can offer some hope in this population group. This will require an outcome study which is unlikely to be carried out.
